Viking Therapeutics, Inc. (VKTX)
NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 61.78 |
| Open | 62.22 |
| Bid | 62.24 x 1200 |
| Ask | 62.36 x 600 |
| Day's range | 61.51 - 63.50 |
| 52-week range | 8.28 - 99.41 |
| Volume | |
| Avg. volume | 4,330,155 |
| Market cap | 6.865B |
| Beta (5Y monthly) | 1.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.92 |
| Earnings date | 24 Jul 2024 - 29 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 113.90 |
ZacksHere's Why Viking Therapeutics, Inc. (VKTX) Gained But Lagged the Market Today
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $62.26, representing a +0.78% change from its previous close.
PR NewswireViking Therapeutics to Participate at Upcoming Investor Conferences
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at two upcoming investor conferences.
ZacksWall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?
The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
© 2024 Yahoo. All rights reserved.